• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

隐形脂质体对HIV-1合成gp41表位免疫原性的佐剂效应

Adjuvanticity of stealth liposomes on the immunogenicity of synthetic gp41 epitope of HIV-1.

作者信息

Singh Sanjay K, Bisen Prakash S

机构信息

Department of Biotechnology, J.C. Bose Institute of Life Sciences, Bundelkhand University, Jhansi 284218, U.P., India.

出版信息

Vaccine. 2006 May 8;24(19):4161-6. doi: 10.1016/j.vaccine.2006.02.047. Epub 2006 Mar 20.

DOI:10.1016/j.vaccine.2006.02.047
PMID:16574286
Abstract

Present study aims to enhance the efficacy of liposomes as an adjuvant by steric protection and strengthen the path of vaccine research. PEG grafted liposomes carrying epitopes on their surface showed enhanced adjuvanticity than liposomes carrying epitopes for elicitation and prolongation of immune response to an antigenic epitope of gp41, a transmembrane protein of HIV-1. The multiples of epitope were incorporated onto the surface of liposomes by conjugating them with phosphatidylethanolamine that was used in the formulation of liposomes at an optimized ratio. Furthermore, the liposomes carrying epitopes on their surface were sterically protected by shielding with methoxy-poly(ethylene glycol), mass 20 kDa. Methoxy-poly(ethylene glycol) was activated to its electrophilic N-succinimide carbonate derivative, methoxy-poly(ethylene glycol)-N-succinimide carbonate, that formed a urethane linkage with the amino group of phosphatidylethanolamine. The epitope was covalently coupled to phosphatidylethanolamine through an amide bond between the -COOH group of the epitope and -NH2 group of phosphatidylethanolamine under the catalysis of 1-ethyl-3-(3-dimethylaminopropy-1)-carbodiimide. PEG grafted epitopes carrying liposomes showed about two times higher immune response and prolonged persistence of antibodies than that of liposomes carrying epitopes without PEG moieties.

摘要

本研究旨在通过空间位阻保护提高脂质体作为佐剂的功效,并加强疫苗研究的途径。表面携带表位的聚乙二醇接枝脂质体比携带表位的脂质体表现出更强的佐剂活性,能够引发和延长对HIV-1跨膜蛋白gp41抗原表位的免疫反应。通过将表位与磷脂酰乙醇胺以优化比例缀合,将多个表位整合到脂质体表面,磷脂酰乙醇胺用于脂质体制剂。此外,表面携带表位的脂质体通过用20 kDa的甲氧基聚(乙二醇)屏蔽进行空间位阻保护。甲氧基聚(乙二醇)被活化成其亲电的N-琥珀酰亚胺碳酸酯衍生物,即甲氧基聚(乙二醇)-N-琥珀酰亚胺碳酸酯,它与磷脂酰乙醇胺的氨基形成脲键。在1-乙基-3-(3-二甲基氨基丙基-1)-碳二亚胺的催化下,表位通过表位的-COOH基团与磷脂酰乙醇胺的-NH2基团之间的酰胺键与磷脂酰乙醇胺共价偶联。携带聚乙二醇接枝表位的脂质体比携带无聚乙二醇部分表位的脂质体表现出约两倍高的免疫反应和延长的抗体持久性。

相似文献

1
Adjuvanticity of stealth liposomes on the immunogenicity of synthetic gp41 epitope of HIV-1.隐形脂质体对HIV-1合成gp41表位免疫原性的佐剂效应
Vaccine. 2006 May 8;24(19):4161-6. doi: 10.1016/j.vaccine.2006.02.047. Epub 2006 Mar 20.
2
Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5.携带HIV gp41表位2F5的嵌合甲型肝炎病毒(HAV)的免疫原性
Antiviral Res. 2007 Feb;73(2):101-11. doi: 10.1016/j.antiviral.2006.08.003. Epub 2006 Sep 5.
3
Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.删除HIV gp41的融合肽或使融合核心不稳定可增强4E10表位的抗原性和免疫原性。
Biochem Biophys Res Commun. 2008 Nov 7;376(1):60-4. doi: 10.1016/j.bbrc.2008.08.105. Epub 2008 Aug 30.
4
[Composition of HIV-1 B-epitopes and heterologous T-cell epitopes. I. Maintenance of antigenic properties of HIV-1 B-epitopes].[HIV-1 B表位与异源T细胞表位的组成。I. HIV-1 B表位抗原特性的维持]
Biokhimiia. 1996 Jul;61(7):1221-9.
5
Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation.HIV-1 gp41膜近端区域的中和表位:基因变异性与共变异性
Immunol Lett. 2006 Aug 15;106(2):180-6. doi: 10.1016/j.imlet.2006.06.002. Epub 2006 Jun 30.
6
Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.具有转运能力的流感血凝素/艾滋病毒包膜嵌合蛋白的抗原特性。
Virology. 2006 Aug 15;352(1):74-85. doi: 10.1016/j.virol.2006.04.012. Epub 2006 May 24.
7
The neutralizing epitope ELDKWA on HIV-1 gp41: genetic variability and antigenicity.
Immunol Lett. 2005 Oct 15;101(1):81-6. doi: 10.1016/j.imlet.2005.04.014.
8
HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.候选CBD1表位疫苗引发的HIV-1中和抗体与病毒糖蛋白gp41保守的小窝蛋白-1结合基序发生反应。
J Pharm Pharmacol. 2006 Jun;58(6):759-67. doi: 10.1211/jpp.58.6.0006.
9
Binding antibody to neutralizing epitope gp41 in HIV-1 subtype CRF 01_AE infection related to stage of disease.在与疾病阶段相关的HIV-1 CRF 01_AE亚型感染中,抗体与中和表位gp41结合。
Southeast Asian J Trop Med Public Health. 2005 Jan;36(1):221-7.
10
Collection of phage-peptide probes for HIV-1 immunodominant loop-epitope.用于HIV-1免疫显性环表位的噬菌体肽探针的收集
J Microbiol Methods. 2007 Feb;68(2):225-35. doi: 10.1016/j.mimet.2006.08.001. Epub 2006 Oct 12.

引用本文的文献

1
Modulation of HIV-1 immunity by adjuvants.佐剂对 HIV-1 免疫的调节。
Curr Opin HIV AIDS. 2014 May;9(3):242-9. doi: 10.1097/COH.0000000000000052.
2
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.纳米技术在预防 HIV/AIDS 中的应用综述。
Biomaterials. 2013 Aug;34(26):6202-28. doi: 10.1016/j.biomaterials.2013.05.012. Epub 2013 May 28.
3
Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.天然样的因子 VIII 聚集体在血管性血友病因子缺乏和血友病 A 小鼠中具有免疫原性。
J Pharm Sci. 2012 Jun;101(6):2055-65. doi: 10.1002/jps.23091. Epub 2012 Mar 2.
4
Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.新兴纳米技术在艾滋病治疗和预防中的应用。
Nanomedicine (Lond). 2010 Feb;5(2):269-85. doi: 10.2217/nnm.10.1.